OPDP slams Facebook page

Share this article:
OPDP slams Facebook page
OPDP slams Facebook page

The latest proof that the FDA is not giving social media outreach wiggle room, even though communications guidelines are not due out until this summer: an untitled letter to Institute Biochimique and US partner Akrimax Pharmaceuticals over a Facebook page for its hypothyroidism drug Tirosint.

The agency's advertising watchdog unit, the Office of Prescription Drug Promotion, slapped the company in its February reprimand for failure to “communicate risk information,” and omission of material facts. This combination qualifies the page as being false and misleading.

Exacerbating the regulator's displeasure is that this is a drug with a boxed warning, a format the FDA sometimes requires to highlight adverse events, contraindications or matters that require a prescriber's additional attention.

In this case, the drug is not indicated for transient hypothyroidism during recovery of subacute thyroditis, should not be used to treat obesity or for weight loss, and should be avoided by patients with acute myocardial infarction or uncorrected adrenal insufficiency.

OPDP says leaving this information out “misleadingly suggests that Tirosint is safer than has been demonstrated.”

Online surveillance is not a new gig for the bad-ad watchdog, and recent analysis by regulatory consultancy Porzio Life Sciences indicates that these two pharmaceutical companies hit the sweet spot of transgressions, in that omission of material facts was a major focus of the unit's 2013 list of violations, as were online communications.

Searching for the Tirosint Facebook page on Google turned up a page with purported patient conversations about the drug at press time, while an in-Facebook search for this page generated a list of drug information from sources including WebMD and the FDA.

Don't miss a free webinar on Thursday, March 13 at 2PM on what the FDA's recent draft guidance means for social media in pharma. Register HERE.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...